Elevated intact proinsulin levels are indicative of beta-cell dysfunction, insulin resistance, and cardiovascular risk: Impact of the antidiabetic agent pioglitazone

Journal of Diabetes Science and Technology

Volumn 5, Issue 3, 2011, Pages 784-793

  Pfützner, Andreas ^a   Forst, Thomas ^a  

^a IKFE   (Germany)

Author keywords

Beta cell dysfunction; Cardiovascular risk; Diabetes; Insulin resistance; Pioglitazone; Proinsulin

Indexed keywords

ATORVASTATIN; GLIBENCLAMIDE; GLIMEPIRIDE; METFORMIN PLUS PIOGLITAZONE; PIOGLITAZONE; PROINSULIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; INSULIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL STUDY; DIABETIC PATIENT; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFECT; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CYTOLOGY; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; PROINSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; THIAZOLIDINEDIONES;

EID: 84857796399     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500333     Document Type: Article

References (50)

1. Reaven GM, Chen YD, Hollenbeck CB, Sheu WH, Ostrega D, Polonsky KS. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab. 1993;76(1):44-8. (Pubitemid 23027550)
2. Haffner SM, Bowsher RR, Mykkänen L, Hazuda HP, Mitchell BD, Valdez RA, Gingerich R, Monterossa A, Stern MP. Proinsulin and specific insulin concentration in high- and low-risk populations for NIDDM. Diabetes. 1994;43(12):1490-3.
3. Røder ME, Porte D Jr, Schwartz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83(2):604-8. (Pubitemid 28496546)
4. Haffner SM, Mykkänen L, Valdez RA, Stern MP, Holloway DL, Monterrosa A, Bowsher RR. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab. 1994;79(6):1806-10.
5. Pfützner A, Standl E, Hohberg C, Konrad T, Strotmann HJ, Lübben G, Langenfeld MR, Schulze J, Forst T. IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design. Diabetes Technol Ther. 2005;7(3):478-86. (Pubitemid 40847810)
6. Pfützner A, Pfützner AH, Larbig M, Forst T. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther. 2004;6(3):405-12. (Pubitemid 38821628)
7. Pfützner A, Pfützner AH, Stridde E, Huppertz E, Reimer T, Derwahl M, Forst T, Petrak F. Insulin resistance and β-cell-dysfunction in insufficiently controlled type 2 diabetes: the SETT2D Trial. Diabetes Stoffwechsel Herz. 2007;2:91-7.
8. Pfützner A, Weber MM, Forst T. A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus. Clin Lab. 2008;54(11-12):485-90.
9. Pfützner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lübben G, Forst T. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care. 2004;27(3):682-7. (Pubitemid 38280533)
10. Pfützner A, Kann PH, Pfützner AH, Kunt T, Larbig M, Weber MM, Forst T. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. Clin Lab. 2004;50(9-10):567- 73. (Pubitemid 39307366)
11. Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, Anderson JH. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care. 1992;15(5):666-92.
12. Pfützner A, Kunt T, Langenfeld M, Löbig M, Knesovic M, Forst T. Clinical and laboratory evaluation of specific chemiluminescence assays for intact and total proinsulin. Clin Chem Lab Med. 2003;41(9):1234-8. (Pubitemid 37265704)
13. Pfützner A, Pfützner AH, Kann PH, Stute R, Löbig M, Yang JW, Mistry J, Forst T. Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin. Clin Lab. 2005;51(5-6):243-9. (Pubitemid 40895123)
14. Siebenhaar R, Weise A, Safinowski M, Reisinger K, Musholt PB, Reimer T, Pfützner A, Forst T. Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin. Diabetes Stoffwechsel Herz. 2008;2:275-81.
15. Lindahl B, Dinesen B, Eliasson M, Røder M, Jansson JH, Huhtasaari F, Hallmans G. High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. Metabolism. 1999;48(9):1197-202. (Pubitemid 29418294)
16. Lindahl B, Dinesen B, Eliasson M, Røder M, Hallmans G, Stegmayr B. High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke. 2000;31(12):2936-41.
17. Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologia. 1996;39(1):113-8. (Pubitemid 26029738)
18. Zethelius B, Byberg L, Hales CN, Lithell H, Berne C. Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation. 2002;105(18):2153-8. (Pubitemid 34517158)
19. Alssema M, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ; Hoorn Study. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care. 2005;28(4):860-5. (Pubitemid 40434486)
20. Båvenholm P, Proudler A, Tornvall P, Godsland I, Landou C, de Faire U, Hamsten A. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation. 1995;92(6):1422-9.
21. Wareham NJ, Byrne CD, Hales CN. Role of insulin and proinsulin in diabetic vascular disease. Metabolism. 1995;44 (10 Suppl 4):76-82.
22. Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey Smith G; Caerphilly Study. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia. 2002;45(3):327-36. (Pubitemid 34267354)
23. Katz RJ, Ratner RE, Cohen RM, Eisenhower E, Verme D. Are insulin and proinsulin independent risk markers for premature coronary artery disease? Diabetes. 1996;45(6):736-41. (Pubitemid 26166768)
24. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007;49(21):2112-9. (Pubitemid 46771048)
25. Langenfeld MR, Forst T, Standl E, Strotmann HJ, Lübben G, Pahler S, Kann P, Pfützner A; IRIS II study. IRIS II Study: sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther. 2004;6(6):836-43. (Pubitemid 40129331)
26. Kubo K. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J. 2002;49(3):323-8. (Pubitemid 34832304)
27. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med. 2004;21(6):568-76. (Pubitemid 38746276)
28. Pfützner A, Hohberg C, Lübben G, Pahler S, Pfützner AH, Kann P, Forst T. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res. 2005;37(8):510-5. (Pubitemid 41306402)
29. Dorkhan M, Magnusson M, Frid A, Grubb A, Groop L, Jovinge S. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. J Intern Med. 2006;260(2):125-33. (Pubitemid 44051337)
30. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C, Hanefeld M. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism. 2007;56(4):491-6. (Pubitemid 46437254)
31. Forst T, Wilhelm B, Pfützner A, Fuchs W, Lehmann U, Schaper F, Weber M, Müller J, Konrad T, Hanefeld M. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res. 2008;5(4):298-303.
32. Cooper MB, Al Majali K, Bailey CJ, Betteridge DJ. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. Clin Endocrinol (Oxf). 2008;68(5):738-46. (Pubitemid 351533447)
33. Charpentier G, Halimi S; F-PIO-100 Study Investigators. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab. 2009;11(9):844-54.
34. Hohberg C, Pfützner A, Forst T, Lübben G, Karagiannis E, Borchert M, Schöndorf T. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study. Diabetes Obes Metab. 2009;11(5):464-71.
35. Musholt PB, Schöndorf T, Pfützner A, Hohberg C, Kleine I, Fuchs W, Hehenwarter S, Dikta G, Kerschgens B, Forst T. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study. J Diabetes Sci Technol. 2009;3(6):1442-50.
36. Pfützner A, Derwahl M, Jacob S, Hohberg C, Blümner E, Lehmann U, Fuchs W, Forst T. Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study. Diabetes Technol Ther. 2010;12(8):599-604.
37. Forst T, Hohberg C, Fuellert SD, Lübben G, Konrad T, Löbig M, Weber MM, Sachara C, Gottschall V, Pfützner A. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res. 2005;37(8):521-7. (Pubitemid 41306404)
38. Smith SA, Porter LE, Biswas N, Freed MI. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(12):6048-53. (Pubitemid 39628413)
39. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care. 2004;27(11):2585-9. (Pubitemid 39441455)
40. Pfützner A, Schöndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, Forst T. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism. 2006;55(1):20-5. (Pubitemid 41736242)
41. Hanefeld M, Patwardhan R, Jones NP; Rosiglitazone Clinical Trials Study Group. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis. 2007;17(1):13-23. (Pubitemid 44881317)
42. Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes. 2008;116(1):6-13. (Pubitemid 351270902)
43. Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC; Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Investigators. Effect of rosiglitazone and ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM Trial. Diabetes Care. 2010;33(3):608-13.
44. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP. Improved beta cell function, with reduction in secretion of intact and 32/33 split proinsulin, after dietary intervention in subjects with type 2 diabetes mellitus. Diabet Med. 1994;11(1):71-8. (Pubitemid 24040546)
45. Byberg L, Zethelius B, McKeigue PM, Lithell HO. Changes in physical activity are associated with changes in metabolic cardiovascular risk factors. Diabetologia. 2001;44(12):2134-9. (Pubitemid 34015465)
46. Nagi DK, Ali VM, Yudkin JS. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabet Med. 1996;13(8):753-7. (Pubitemid 26252956)
47. Hermann LS, Ranstam J, Vaaler S, Melander A. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes. Diabetes Obes Metab. 1999;1(4):227-32.
48. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP. Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus. Diabet Med. 1994;11(3):293-8. (Pubitemid 24144146)
49. Dworacka M, Abramczyk M, Winiarska H, Kuczynski S, Borowska M, Szczawinska K. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea. Int J Clin Pharmacol Ther. 2006;44(1):14-21. (Pubitemid 43085493)
50. Pfützner A, Lorra B, Abdollahnia MR, Kann PH, Mathieu D, Pehnert C, Oligschleger C, Kaiser M, Forst T. The switch from sulfonylurea to preprandial short-acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2006;8(3):375-84. (Pubitemid 46100531)